Celltrion to Buy Back Treasury Shares Worth 100 Billion Won, Cumulative 400 Billion Won This Year

Implementing the Principle of Returning One-Third of Consolidated Net Profit to Shareholders
Collecting Shareholder Opinions at the March 2027 Annual General Meeting

Celltrion announced on September 29 that its board of directors has decided to repurchase additional treasury shares worth approximately 100 billion won.

The treasury shares to be purchased this time total 560,853 shares, amounting to about 100 billion won based on the closing price on the day before the board resolution. The share buyback will be carried out through on-market purchases from the following day until December 29. With this decision, the cumulative value of treasury shares that Celltrion has decided to repurchase this year will reach 400 billion won.

Celltrion stated, "This buyback was undertaken to stabilize the share price and enhance shareholder value, based on the assessment that the current share price is undervalued compared to the company's intrinsic value and mid- to long-term growth potential." The company also added, "After finalizing the treasury share repurchase, we will comprehensively review whether the cancellation of these shares or an increase in cash dividends would provide greater real benefits to shareholders."

Celltrion is adhering to its policy of returning one-third of its annual consolidated net profit to shareholders, either through the cancellation of treasury shares or by increasing cash dividends, as a mid- to long-term principle.

Whether the treasury shares repurchased this time will be cancelled or not will be decided after fully collecting shareholder opinions at the regular shareholders' meeting scheduled for March 2027. The company intends to choose the method—either treasury share cancellation or an increase in cash dividends—that maximizes the actual return to shareholders, reflecting both shareholder feedback and market conditions.

Celltrion continues its growth momentum in key global markets, including the United States and Europe, based on the expanded prescriptions of flagship products such as Zymfentra as well as new products. The company plans to further solidify its virtuous cycle structure by executing R&D and production capacity investments as planned, while maintaining consistent shareholder returns based on stable free cash flows.

A Celltrion official commented, "This additional treasury share repurchase was decided with confidence in the company's robust fundamentals and mid- to long-term growth prospects," adding, "We will pursue a balanced approach to growth investment and shareholder returns in line with our commitment to return one-third of our consolidated net profit to shareholders."

This content was produced with the assistance of AI translation services.